Skip to main content
. 2024 Feb 8;13(2):415–435. doi: 10.1007/s40120-024-00582-0

Fig. 5.

Fig. 5

Proportion of patients with at least a 50% MMD reduction by medication overuse. “Most recent time point” either refers to the time frame “month 13 to month 15 during follow-up” or “1 to 3 months after galcanezumab treatment interruption.” MMDs Monthly migraine days, MOH medication overuse headache, n number of patients who achieved at least a 50% MMDs reduction from baseline, nMOH no medication overuse headache, SD standard deviation